Sinovac Schedules 2013 Annual Meeting of Shareholders

            Sinovac Schedules 2013 Annual Meeting of Shareholders

PR Newswire

BEIJING, July 19, 2013

BEIJING, July 19, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a
leading provider of biopharmaceutical products in China, announced today that
it will hold its 2013 Annual Meeting of Shareholders on Wednesday, August 21,
2013 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi
Road, Haidian District, Beijing, PRC. All shareholders of record as of July 3,
2013 will be eligible to vote and are invited to attend.

The primary agenda of the meeting is to approve the re-election of Weidong
Yin, Yuk Lam Lo, Simon Anderson, Kenneth Lee and Meng Mei as the Company's
directors until the next annual meeting of shareholders and or until their
successors are duly elected; approve the audited consolidated financial
statements of the Company for the financial year ended December 31, 2012
together with the Report of Independent Registered Public Accounting Firm
thereon and the notes thereto; approve the appointment of Ernst &Young Hua
Ming LLP as the independent auditor of the Company for the fiscal year ending
December 31, 2013 and to authorize the directors of the Company to fix such
independent auditor's remuneration.

Sinovac's 2012 annual report and proxy statements, including the Notice of the
2013 Annual General Meeting, are available on the Company's website:
http://www.sinovac.com/?optionid=751.

Shareholders of the Company may receive a hard copy of 20-F free of charge
upon request. Such request can be made by sending an e-mail to ir@sinovac.com,
along with complete contact details and a mailing address.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacturing and commercialization of vaccines
that protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine
flu) and mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease). In 2009, Sinovac was the first company
worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and
has manufactured it for the Chinese Central Government, pursuant to the
government-stockpiling program. The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac
is developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license
to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028
Email: aestrada@theruthgroup.com







SOURCE Sinovac Biotech Ltd.

Website: http://www.sinovac.com/?optionid=751